首页> 美国卫生研究院文献>The FASEB Journal >Epithelial chemokine CXCL14 synergizes with CXCL12 via allosteric modulation of CXCR4
【2h】

Epithelial chemokine CXCL14 synergizes with CXCL12 via allosteric modulation of CXCR4

机译:上皮趋化因子CXCL14通过CXCR4的变构调节与CXCL12协同作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The chemokine receptor, CXC chemokine receptor 4 (CXCR4), is selective for CXC chemokine ligand 12 (CXCL12), is broadly expressed in blood and tissue cells, and is essential during embryogenesis and hematopoiesis. CXCL14 is a homeostatic chemokine with unknown receptor selectivity and preferential expression in peripheral tissues. Here, we demonstrate that CXCL14 synergized with CXCL12 in the induction of chemokine responses in primary human lymphoid cells and cell lines that express CXCR4. Combining subactive concentrations of CXCL12 with 100–300 nM CXCL14 resulted in chemotaxis responses that exceeded maximal responses that were obtained with CXCL12 alone. CXCL14 did not activate CXCR4-expressing cells (i.e., failed to trigger chemotaxis and Ca2+ mobilization, as well as signaling via ERK1/2 and the small GTPase Rac1); however, CXCL14 bound to CXCR4 with high affinity, induced redistribution of cell-surface CXCR4, and enhanced HIV-1 infection by >3-fold. We postulate that CXCL14 is a positive allosteric modulator of CXCR4 that enhances the potency of CXCR4 ligands. Our findings provide new insights that will inform the development of novel therapeutics that target CXCR4 in a range of diseases, including cancer, autoimmunity, and HIV.—Collins, P. J., McCully, M. L., Martínez-Muñoz, L., Santiago, C., Wheeldon, J., Caucheteux, S., Thelen, S., Cecchinato, V., Laufer, J. M., Purvanov, V., Monneau, Y. R., Lortat-Jacob, H., Legler, D. F., Uguccioni, M., Thelen, M., Piguet, V., Mellado, M., Moser, B. Epithelial chemokine CXCL14 synergizes with CXCL12 via allosteric modulation of CXCR4.
机译:趋化因子受体CXC趋化因子受体4(CXCR4)对CXC趋化因子配体12(CXCL12)具有选择性,在血液和组织细胞中广泛表达,在胚胎发生和造血过程中至关重要。 CXCL14是一种稳态趋化因子,具有未知的受体选择性和在周围组织中的优先表达。在这里,我们证明了CXCL14与CXCL12协同诱导了原代人淋巴样细胞和表达CXCR4的细胞系中的趋化因子反应。将亚活性浓度的CXCL12与100–300 nM CXCL14结合使用时,趋化性反应超过了仅使用CXCL12可获得的最大反应。 CXCL14不能激活表达CXCR4的细胞(即未能触发趋化性和Ca 2 + 动员,也无法通过ERK1 / 2和小的GTPase Rac1发出信号)。但是,CXCL14以高亲和力与CXCR4结合,诱导细胞表面CXCR4的重新分布,并使HIV-1感染增加3倍以上。我们假设CXCL14是CXCR4的正变构调节剂,可增强CXCR4配体的效力。我们的发现提供了新的见识,这些新见识将为针对多种疾病(包括癌症,自身免疫性疾病和HIV)中针对CXCR4的新型疗法的发展提供参考。 ,Wheeldon J.,Caucheteux S.,Thelen S.,Cecchinato V.,Laufer JM,Purvanov V.,Monneau YR,Lortat-Jacob H.Legler DF Uguccioni M. Thelen,M.,Piguet,V.,Mellado,M.,Moser,B.上皮趋化因子CXCL14通过CXCR4的变构调节与CXCL12协同作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号